IP LICENSING · FORMULATION & DELIVERY

TechnologyLicensing.

Continuum Innovative licenses its formulations, its delivery technology and its patent-pending programs to partners who want to build inside their own brand rather than distribute ours. Seven proprietary IP programs are currently the subject of provisional patent applications; none of them is described here as an issued patent.

Licensing suits organizations with their own brand equity, their own channel, and the intention to own a differentiated position.

FILED USPTO PROVISIONAL IP PROGRAMS

PEER-REVIEWED PUBLICATIONS

DECADES OF FOLLICULAR RESEARCH

COMMERCIALIZED BRANDS

WHAT IS LICENSABLE

Four distinct assets.

A license may cover one asset or several, in a defined field of use and territory. The structure follows the commercial intention rather than a fixed template.

Formulations

The HairGenesis® oral TrichoCeutical™ and topical activator formulations, and the TrichoCyte™ botanical composition.

Delivery technology

The β-cyclodextrin inclusion-complex approach that pairs botanical actives with a delivery vector rather than relying on the active alone.

Patent-pending programs

The seven-program provisional portfolio covering immune privilege, intracrine androgen dynamics, senescence biology, multi-nodal stabilization, perimenopausal destabilization, follicle–stromal field biology, and convergent privilege collapse.

Claim and evidence substance

The peer-reviewed literature and mechanism documentation that a marketing claim set has to rest on if it is going to survive regulatory and retailer scrutiny.

THE IP POSITION, STATED PRECISELY

Patent-pending — and described as such.

Continuum's current generation of programs is protected by concurrent USPTO provisional applications. The autoimmune loss-of-privilege program is filed under provisional 64/065,059. Provisional applications establish priority; they are not issued patents, and we do not describe them as issued patents in any partner conversation, diligence document or public page.

For a licensee, the practical significance is priority date, defined scope and a documented invention record — not an enforceable granted claim set. Any partner evaluating the portfolio should read it on exactly those terms, and the public filing numbers and dates are available now; nonpublic claim strategy and technical materials follow under confidentiality.

Autoimmune loss of privilege — provisional 64/065,059.
Intracrine dynamics — local follicular androgen metabolism.
Senescence biology and multi-nodal stabilization.
Perimenopausal destabilization, plus follicular–stromal field dynamics and convergent privilege collapse.

LICENSING STRUCTURES

How these are normally shaped.

Territory license.

Rights to manufacture or market a licensed formulation within a defined country or region, typically with agreed performance conditions attached to exclusivity.

Field-of-use license.

Rights limited to a defined channel or application — for example pharmacy retail, physician-dispensed protocols, or a professional clinic line — leaving other fields open.

Private-label and brand license.

The licensee's own brand carries the product, with the underlying formulation, delivery technology and evidence supplied by Continuum.

Co-development license.

A formulation is developed jointly against the partner's commercial specification, with ownership and rights agreed in advance rather than assumed.

What is not on the table.

Continuum is not offered for acquisition, and neither is the IP portfolio. The relationships we pursue are licensing, co-development, distribution, commercialization and strategic investment — all of which keep the platform intact and continuing to develop.

III

BEFORE YOU LICENSE ANYTHING

Evaluate it properly — including ours.

We publish our own evaluation methodology rather than asking partners to take the science on trust. If you are assessing a hair-growth ingredient or technology — from us or from anyone else — the Continuum Translational Assessment Framework™ sets out the nine dimensions that actually determine whether an asset is licensable, and the flagship evaluation note works through the decision in full.

Applying that framework to Continuum's own portfolio is the fastest way to establish whether a license is worth your time.

Partnership pathwaysAll available relationship structures.Intellectual propertyThe programs, in scientific detail.Due-diligence packageWhat we send a serious licensee.Licensing & distribution FAQDirect answers, including on exclusivity.PublicationsThe peer-reviewed record underlying the claims.Strategic Scientific EvaluationHow to evaluate any licensing candidate.

NEXT STEP

Tell us the field of use you have in mind.

Brand, channel, territory and intended positioning. That is enough for us to say whether a license is the right structure — or whether distribution or co-development fits better.

DISCUSS A LICENSE

GCC HUB

Continuum Innovative in the GCCGCC Strategic Partnerships & Investment

The regional gateway: the platform, the science, the intellectual property, and the forms of strategic relationship Continuum will discuss with Gulf organizations.